Rua Releases Half-Year Result – Results as expected, with German launch imminent
The Group reported a net profit after tax of $718,703 for the period ending 31 December 2022. Excluding fair value gain on contingent consideration of $4,100,932, the Group incurred an operating loss of $3,382,229.
The results are in line with expectations as the company established its product and revenue pipelines and further positioned itself to compete globally.
Update on the Impact of Cyclone Gabrielle
Rua Bioscience provides the following update on its operations in the wake of the regional disruptions caused by Cyclone Gabrielle.
Rua Announces Appointment of New CEO and Chair
Rua Bioscience has appointed Paul Naske as Chief Executive Officer. Interim Managing Director, Anna Stove, will return to Chair the Rua Board as Trevor Burt announces his retirement.
Rua Releases Annual Results for the 12 months ended 30 June 2022
Director, Martin Smith, to Retire. AGM Date Set.
The Board of Directors of Rua Bioscience Limited advises that Mr Martin Smith has decided to retire as an Independent Non-Executive Director. Martin’s retirement will be effective at the conclusion of the 2022 Annual General Meeting scheduled for October 12, 2022.
Rua Bioscience CEO Rob Mitchell to retire - Anna Stove appointed Managing Director
Rua Bioscience Chief Executive Officer Rob Mitchell has advised the Board of his intention to retire from his role effective 1 September 2022.
Rua Chair Trevor Burt said that Rob Mitchell has built on the company’s solid foundations, leading Rua through significant milestones and developing new strategic partnerships.
Announcement of Director Appointment
The Chair of Rua Bioscience, Mr Trevor Burt, and the Rua Board are delighted to announce the appointment of Teresa Ciprian as an Independent Non-Executive Director, effective 1 August 2022.